Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 145.21M P/E - EPS this Y -22.70% Ern Qtrly Grth -
Income -39.33M Forward P/E 2.23 EPS next Y 114.80% 50D Avg Chg -23.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book 1.47 EPS next 5Y - 52W High Chg -47.00%
Recommedations 2.00 Quick Ratio 3.65 Shares Outstanding 159.10M 52W Low Chg 19.00%
Insider Own 7.74% ROA -23.21% Shares Float 146.77M Beta 1.43
Inst Own 17.00% ROE -40.97% Shares Shorted/Prior 11.61M/14.62M Price 0.91
Gross Margin - Profit Margin - Avg. Volume 2,028,708 Target Price -
Oper. Margin - Earnings Date May 10 Volume 1,696,404 Change -4.26%
About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc. News
02/23/24 Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
02/14/24 Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
02/14/24 Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
02/11/24 Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
01/23/24 Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
01/02/24 Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
01/02/24 Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
12/03/23 We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
11/14/23 Sidoti Events, LLC’s Virtual November Micro-Cap Conference
11/09/23 Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
10/31/23 Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
10/24/23 Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
09/21/23 Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
09/18/23 Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
09/13/23 Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
09/08/23 Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™
09/06/23 Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
08/14/23 Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
08/10/23 Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
07/29/23 Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
CTXR Chatroom

User Image Daddy044 Posted - 14 hours ago

$CTXR No Financing. Likely the company filed a shelf to be prudent. Too much good news potentially on the horizon.

User Image Pillars Posted - 1 day ago

$CTXR The management will fail just like the country he came from. As simple as that.

User Image FutureInvesting777 Posted - 1 day ago

$CTXR what is the deal with the S3 and S8 filed yesterday?

User Image Worknpaint Posted - 1 day ago

$CTXR hmmm

User Image Worknpaint Posted - 1 day ago

$CTXR M & A you say?

User Image Worknpaint Posted - 1 day ago


User Image DonCorleone77 Posted - 1 day ago

$CTXR Citius Pharmaceuticals files $250M mixed securities shelf

User Image PoorManRising Posted - 2 days ago

$CTXR I see not much has changed here as expected. Still have cash problems. But I have to hand it to them, I had them pegged for a BK candidate and they’re still alive! I made some cash here last year, but probably won’t invest in CTXR because they are planning to spin this BLA into a separate company upon approval. This complicates the value to CTXR investors. They will stay on my DNB list.

User Image Bob4Baker Posted - 2 days ago

$CTXR another conference? Neat!!!

User Image RHEMVS Posted - 2 days ago

$CTXR wow. You guys start your happy hour early? Figured there would be a full on shit storm with $250 m shelf news drop.

User Image Keepitmoving Posted - 2 days ago

$CTXR soon this turd is going to completely implode. FU Leonard

User Image Icantgetup Posted - 2 days ago

$CTXR Hold on tight. This will be earth shaking news.

User Image CliffordCapital Posted - 2 days ago

@GrizzliesTwits ye I agree… $CTXR looks more interesting but itrm market cap just 16M lol

User Image MarketForecasting Posted - 2 days ago

$CTXR Leonard has put Jesse Livermore’s thesis to shame "It was never my thinking that made the big money for me, it always was sitting. sitting tight."

User Image MarketForecasting Posted - 2 days ago

$CTXR still a pullback ? Ha ha

User Image Stock_Titan Posted - 2 days ago

$CTXR Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences https://www.stocktitan.net/news/CTXR/citius-pharmaceuticals-to-participate-in-upcoming-bio-ceo-and-sidoti-p8ym3zahcan2.html

User Image UniversalIntelect Posted - 3 days ago

$CTXR still borrowing. They will FAIL

User Image Speednlux Posted - 3 days ago

$CTXR I know there are many of us holding heavy bags (myself included since 21) but I’m certain that if you sell at the first opportunity to break even on the run up you will regret it

User Image GaryBezos Posted - 3 days ago

$CTXR one year gap of $1.65 is coming soon . Can mid April help us mov and fill that gap up to 1.50 👀 ??

User Image FutureInvesting777 Posted - 3 days ago

$CTXR VINC keeps going up.

User Image opplebot Posted - 3 days ago

$CTXR last week this thing was getting carried away guys, we broke 0.80 for the first time in months. Thank goodness we had a nice healthy pullback and are back in the 0.70s. we wouldn't want this thing to be overbought or anything. 😌

User Image Kevin__P Posted - 3 days ago

$CTXR Market getting swallowed by the "Mag 6" today and taking all the attention. Bought NVDA pre earnings yesterday after seeing it was down 4 straight days. Money! Our day here still lie's ahead, and these market pumps will head our way when the fun wears off.

User Image Balci Posted - 3 days ago

$CTXR Last 26 days of work in the 2nd quarter

User Image steinerstreet Posted - 4 days ago

$CTXR just 40 days until Q2. 40 days potentially until TLD.

User Image Icantgetup Posted - 4 days ago

$CTXR I don't know if it means SP will increase but $TENKU closed at $11.93 (ATH).

User Image MarketForecasting Posted - 4 days ago

$CTXR I’m sure most here just want to sell this shit before mini lok tld

User Image drrotinaj Posted - 4 days ago

$CTXR Growth. Slow n' Steady

User Image opplebot Posted - 4 days ago


User Image Cooch23 Posted - 4 days ago

$CTXR curious how they don’t make money with liziness?

User Image shinseiRomeo Posted - 4 days ago

$CTXR I've been in Citius for years and unfortunately in the red. I'm considering doubling down at the current price under $1 though the outlook/prospectus/DD I've done doesn't show significant positive growth. I miss the good old days off 2022!

Analyst Ratings
HC Wainwright & Co. Buy Feb 14, 24
HC Wainwright & Co. Buy Aug 10, 23
HC Wainwright & Co. Buy Aug 1, 23
HC Wainwright & Co. Buy May 30, 23
HC Wainwright & Co. Buy Apr 3, 23
HC Wainwright & Co. Buy Mar 29, 23
HC Wainwright & Co. Buy Jan 18, 22
Maxim Group Buy Nov 30, 21
H.C. Wainwright Buy May 23, 18